MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Location
Founded
1989-12-19
Website
Risk Signals
4971 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Surgical and Medical Instruments and Apparatus, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Live alerts from global media, monitored by Business Radar
2025-04-30 (informa.com)
Medtronic Presents Data To Boost Hugo's Odds Of Getting FDA Nod
Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.
Read more
2025-04-28 (pharmabiz.com)
Medtronic receives US FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure lead
Medtronic plc, a global leader in healthcare technology, received US Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure Model 3830 pacing lead and delivered via catheter, builds on the Medtronic portfolio of lead solutions designed for precise delivery and placement. The lead connects to an implantable defibrillator, and treats potentially life threatening ventricular tachyarrhythmias, ventricular fibrillation (VT/VF) and bradyarrhythmias. As the world's smallest defibrillation lead (4.7 French, or 1.6mm), the OmniaSecure lead represents a meaningful innovation in electrophysiology, and is indicated for stimulation in the right ventricle for adults and adolescent paediatric patients ages 12 and up, including those with smaller anatomies.
Read more
2025-04-26 (massdevice.com)
Medtronic submits Hugo surgical robot to FDA, meets trial endpoints
Medtronic (NYSE:MDT) announced today that it recently submitted its Hugo surgical robot platform to the FDA for a urologic indication.
Read more
2025-04-26 (investorshangout.com)
Medtronic's Hugo™ RAS System Achieves Key Clinical Trial Milestone - Investors Hangout
Medtronic's Hugo™ RAS System meets critical safety and effectiveness endpoints in pivotal clinical trial, signaling a major advancement in robotic surgery.
Read more
2025-04-26 (simplywall.st)
Medtronic (NYSE:MDT) Secures FDA Approval For Innovative OmniaSecure Defibrillation Lead - Simply Wall St News
Medtronic (NYSE:MDT) recently announced FDA approval of its OmniaSecure™ defibrillation lead, marking a key advancement in cardiovascular technology, along with results from its LEADR LBBAP study showing a 100% defibrillation success rate. Over the past week, Medtronic's stock price increased by 1.9%, a move that aligned with these positive developments but was modest compared to the broader market's 4.7% rise. While Medtronic's innovative product developments could have added weight to its...
Read more
2025-04-24 (medtechdive.com)
Medtronic seeks FDA nod for insulin pump, furthering Abbott collab |
Receiving FDA clearance would allow Medtronic to pair its pumps with a glucose monitor being developed for the company by Abbott.
Read more
2025-04-21 (bioworld.com)
Medtronic continues to close gap in diabetes tech |
Medtronic plc's diabetes unit posted another win with the U.S. FDA approval of the Simplera continuous glucose monitoring sensor for use with the Minimed 780G pump system, helping the company catch up with competitors Abbott Laboratories and Dexcom Inc. Medtronic plans to begin a limited launch of the Simplera Sync in the U.S. this fall.
Read more
2025-04-21 (drugdeliverybusiness.com)
Medtronic wins FDA nod for new Simplera Sync CGM with MiniMed 780G
Medtronic announced that the FDA approved its Simplera Sync continuous glucose monitor for use with the MiniMed 780G.
Read more
2025-04-19 (investorshangout.com)
Medtronic Expands Diabetes Management with Simplera Sync™ Sensor - Investors Hangout
Medtronic announces FDA approval for the Simplera Sync™ sensor, enhancing the MiniMed™ 780G system and expanding diabetes management options for users.
Read more
2025-04-18 (rttnews.com)
Medtronic Gets FDA Approval For Simplera Sync Sensor For MiniMed 780G System
Medtronic plc. (MDT) announced the U.S. Food and Drug Administration approval for the Simplera Sync sensor for use with the MiniMed 780G system. The MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.
Read more
2025-04-06 (finanznachrichten.de)
Medtronic plc: Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure lead and announces investigational clinical study results
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricleHeart Rhythm 2025:
Read more
2025-03-31 (fool.com)
Why Medtronic Stock Marched Higher on Monday |
Medtronic (MDT 2.62%) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by almost 3% in value. They liked the medical device specialist's latest piece of news about one of its products, and reacted accordingly. The stock's gain easily topped that of the S&P 500 (^GSPC 0.55%), which closed the day up 0.6%.
Read more